BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Raised by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 65,213.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 542,100 shares of the biotechnology company's stock after acquiring an additional 541,270 shares during the quarter. Hillsdale Investment Management Inc. owned approximately 0.26% of BioCryst Pharmaceuticals worth $4,077,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $48,000. KBC Group NV raised its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $80,000. Finally, Quantinno Capital Management LP acquired a new position in BioCryst Pharmaceuticals in the third quarter worth about $82,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on BCRX shares. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities restated a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, January 13th. Royal Bank of Canada reissued an "outperform" rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $15.57.

Remove Ads

BioCryst Pharmaceuticals Stock Up 0.4 %

BCRX stock traded up $0.03 during mid-day trading on Thursday, reaching $7.83. The company had a trading volume of 1,289,217 shares, compared to its average volume of 2,749,287. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The stock has a market capitalization of $1.64 billion, a P/E ratio of -12.84 and a beta of 1.85. The stock's 50-day simple moving average is $8.17 and its two-hundred day simple moving average is $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same quarter in the previous year, the company posted $0.28 EPS. The firm's revenue was up 40.8% compared to the same quarter last year. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.